Approval · Notice of Compliance 26029 · 2021
MENVEO: Notice of Compliance 26029
Issued June 8, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26029
- Date
- June 8, 2021
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New master seed bank
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MENVEO | Not yet assigned | — |
Medicinal ingredients
- CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN 47 MCG per 0.5ML
- MENINGOCOCCAL GROUP A OLIGOSACCHARIDE 10 MCG per 0.5ML
- MENINGOCOCCAL GROUP C OLIGOSACCHARIDE 5 MCG per 0.5ML
- MENINGOCOCCAL GROUP W-135 OLIGOSACCHARIDE 5 MCG per 0.5ML
- MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE 5 MCG per 0.5ML